
Lora Hamuro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10061558/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2017, 106, 2946-2954.	3.3	58
2	Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Timeâ€Varying Clearance. Clinical Pharmacology and Therapeutics, 2019, 106, 1018-1027.	4.7	15
3	Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Sixâ€Minute Walk Test. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 596-603.	2.5	13
4	Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. Clinical and Translational Science, 2020, 13, 219-223.	3.1	11
5	Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. AAPS Journal, 2019, 21, 94.	4.4	10
6	Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 748-759.	2.5	3
7	Exposure–Response Analysis to Support Nivolumab Once Every 4 Weeks Dosing in Combination with Cabozantinib in Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 1603-1613.	7.0	3
8	Changing the Drug Development and Therapeutic Paradigm with Biologic Drug Combinations and Bispecifics: How to Choose Between These Two Approaches?. Clinical and Translational Science, 0, , .	3.1	2